6 studies on Hpa axis mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**GHRP-2 may offer a clinically viable, lower-risk alternative to ITT** for diagnosing secondary adrenal insufficiency in patients with hypopituitarism — a group in whom insulin-induced hypoglycemia carries elevated d…
**Clinicians and peptide users co-administering testosterone with GHRP-2 should recognize that testosterone itself — not its aromatized or 5alpha-reduced metabolites — is the primary amplifier of GHRP-2-driven pulsati…
**Clinicians and users employing GHRP-2 in hormonal contexts must account for background androgen status**: higher DHT strongly attenuates stimulated cortisol pulsatility, meaning men on 5α-reductase inhibitors (e.g.,…
**MK-0677's entire hormonal efficacy — both IGF-I elevation and cortisol rise — is pituitary-gated**, meaning any context that compromises hypothalamic-pituitary function (severe illness, pituitary adenoma, prior radi…
**Clinicians and peptide users combining GHS with GHRH analogs** (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalami…
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot a…